TNBC is a diverse group of breast cancers lacking expression of estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER2), and therefore lacks biomarker-directed therapeutic options that are available and have been applied with remarkable success in other breast cancer subtypes. This evidence concerns the gene ERBB2 and breast carcinoma.